Business Description
Hepion Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US21234W2026
Description
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.67 | |||||
| Equity-to-Asset | -0.11 | |||||
| Debt-to-Equity | -5.46 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 33.3 | |||||
| 3-Year EPS without NRI Growth Rate | 35.3 | |||||
| 3-Year FCF Growth Rate | 32.6 | |||||
| 3-Year Book Growth Rate | -63.7 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 12-1 Month Momentum % | -39.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | |||||
| Quick Ratio | 1.3 | |||||
| Cash Ratio | 0.55 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -44.4 | |||||
| Shareholder Yield % | -16.96 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -332.76 | |||||
| ROA % | -164.98 | |||||
| ROIC % | -947.24 | |||||
| ROC (Joel Greenblatt) % | -1964.39 | |||||
| ROCE % | -295.63 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.19 | |||||
| EV-to-EBITDA | -0.19 | |||||
| EV-to-FCF | -0.22 | |||||
| Earnings Yield (Greenblatt) % | -526.32 | |||||
| FCF Yield % | -814.05 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hepion Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | 0 | ||
| Beta | 0 | ||
| Volatility % | 27.77 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 9.2 | ||
| 12-1 Month Momentum % | -39.73 | ||
| 52-Week Range (€) | 9.2 - 16.18 | ||
| Shares Outstanding (Mil) | 4.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hepion Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hepion Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hepion Pharmaceuticals Inc Frequently Asked Questions
What is Hepion Pharmaceuticals Inc(FRA:336)'s stock price today?
The current price of FRA:336 is €9.20. The 52 week high of FRA:336 is €16.18 and 52 week low is €9.20.
When is next earnings date of Hepion Pharmaceuticals Inc(FRA:336)?
The next earnings date of Hepion Pharmaceuticals Inc(FRA:336) is 2025-02-14 Est..
Does Hepion Pharmaceuticals Inc(FRA:336) pay dividends? If so, how much?
Hepion Pharmaceuticals Inc(FRA:336) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers